Quick Answer
MIMEDX GROUP, INC. reported Total Revenue of $418.63 million for fiscal year 2025.
MIMEDX GROUP, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $418.63M +20.0% |
$348.88M +8.5% |
$321.48M +20.0% |
$267.84M +10.7% |
$242.02M -2.5% |
$248.23M -17.0% |
| Revenue (ASC 606) | $418.63M +20.0% |
$348.88M +8.5% |
$321.48M +20.0% |
$267.84M +10.7% |
$242.02M -2.5% |
$248.23M -17.0% |
| Net Income | $48.58M +14.5% |
$42.42M -27.2% |
$58.23M +292.8% |
-$30.20M -193.6% |
-$10.29M +79.1% |
-$49.28M -92.7% |
| Diluted EPS | $0.32 +14.3% |
$0.28 -24.3% |
$0.37 +212.1% |
-$0.33 -120.0% |
-$0.15 +80.5% |
-$0.77 -220.8% |
| Total Assets | $342.65M +29.8% |
$263.92M +10.4% |
$239.05M +39.4% |
$171.43M -8.8% |
$187.93M -7.0% |
$202.03M +20.9% |
| Cash and Equivalents | $166.12M +59.1% |
$104.42M +27.3% |
$82.00M +24.3% |
$65.95M -24.3% |
$87.08M -9.1% |
$95.81M +38.7% |
| Long-Term Debt | $16.47M -7.6% |
$17.83M -62.9% |
$48.10M -1.0% |
$48.59M +1.0% |
$48.13M +0.9% |
$47.70M -23.0% |
| Stockholders Equity | $256.55M +32.9% |
$193.11M +35.3% |
$142.72M +893.4% |
-$17.99M -22036.6% |
$82.0K +154.7% |
-$150.0K -100.4% |
| R&D Expense | $15.10M +22.3% |
$12.34M -2.6% |
$12.66M -0.3% |
$12.70M +27.9% |
$9.93M -15.2% |
$11.71M +5.2% |
| Operating Income | $63.89M +8.5% |
$58.87M +58.6% |
$37.12M +352.0% |
-$14.73M -108.9% |
-$7.05M +84.5% |
-$45.40M -114.5% |
| Gross Profit | $345.62M +19.7% |
$288.81M +8.2% |
$266.84M +21.6% |
$219.53M +8.5% |
$202.39M -3.1% |
$208.90M -18.5% |
| Shares Outstanding | 148.09M +0.8% |
146.93M +0.5% |
146.23M +28.6% |
113.71M +1.6% |
111.93M +0.9% |
110.93M +0.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $113.72M | +35.3% | +15.3% |
| Revenue (ASC 606) | September 30, 2025 | $113.72M | +35.3% | +15.3% |
| Net Income | September 30, 2025 | $16.75M | +106.9% | +74.1% |
| Diluted EPS | September 30, 2025 | $0.11 | +120.0% | +83.3% |
| Total Assets | September 30, 2025 | $318.99M | +30.8% | +9.6% |
| Cash and Equivalents | September 30, 2025 | $142.08M | +60.0% | +19.5% |
| Long-Term Debt | September 30, 2025 | $16.84M | -6.5% | -2.2% |
| Stockholders Equity | September 30, 2025 | $238.95M | +32.0% | +10.3% |
| R&D Expense | September 30, 2025 | $3.70M | +26.9% | +12.1% |
| Operating Income | September 30, 2025 | $22.19M | +98.8% | +79.4% |
| Gross Profit | September 30, 2025 | $95.01M | +38.2% | +18.9% |
| Shares Outstanding | September 30, 2025 | 148.08M | +0.8% | +0.1% |
- MIMEDX GROUP, INC. reported Total Revenue of $418.63 million for fiscal year 2025.
- MIMEDX GROUP, INC. showed an increase of +20.0% in Total Revenue compared to the prior fiscal year.
- MIMEDX GROUP, INC. reported Revenue (ASC 606) of $418.63 million for fiscal year 2025.
- MIMEDX GROUP, INC. showed an increase of +20.0% in Revenue (ASC 606) compared to the prior fiscal year.
- MIMEDX GROUP, INC. reported Net Income of $48.58 million for fiscal year 2025.
- MIMEDX GROUP, INC. showed an increase of +14.5% in Net Income compared to the prior fiscal year.
- MIMEDX GROUP, INC. reported Diluted EPS of $0.32 per share for fiscal year 2025.
- MIMEDX GROUP, INC. showed an increase of +14.3% in Diluted EPS compared to the prior fiscal year.
- MIMEDX GROUP, INC. reported Total Assets of $342.65 million for fiscal year 2025.
- MIMEDX GROUP, INC. showed an increase of +29.8% in Total Assets compared to the prior fiscal year.
- MIMEDX GROUP, INC. reported Cash and Equivalents of $166.12 million for fiscal year 2025.
- MIMEDX GROUP, INC. showed an increase of +59.1% in Cash and Equivalents compared to the prior fiscal year.
- MIMEDX GROUP, INC. reported Long-Term Debt of $16.47 million for fiscal year 2025.
- MIMEDX GROUP, INC. showed a decrease of -7.6% in Long-Term Debt compared to the prior fiscal year.
- MIMEDX GROUP, INC. reported Stockholders Equity of $256.55 million for fiscal year 2025.
- MIMEDX GROUP, INC. showed an increase of +32.9% in Stockholders Equity compared to the prior fiscal year.
- MIMEDX GROUP, INC. reported R&D Expense of $15.10 million for fiscal year 2025.
- MIMEDX GROUP, INC. showed an increase of +22.3% in R&D Expense compared to the prior fiscal year.
- MIMEDX GROUP, INC. reported Operating Income of $63.89 million for fiscal year 2025.
- MIMEDX GROUP, INC. showed an increase of +8.5% in Operating Income compared to the prior fiscal year.
- MIMEDX GROUP, INC. reported Gross Profit of $345.62 million for fiscal year 2025.
- MIMEDX GROUP, INC. showed an increase of +19.7% in Gross Profit compared to the prior fiscal year.
- MIMEDX GROUP, INC. reported Shares Outstanding of 148.09 million shares for fiscal year 2025.
- MIMEDX GROUP, INC. showed an increase of +0.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: